Impact of genetic testing family screening in hereditary transthyretin amyloidosis

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Nerea Mora Ayestaran

Navarra University Hospital, Pamplona, Navarra (Spain)

7 More presentations in this session

Presentation thumbnail

Diagnostic prediction model for cardiac amyloidosis due to transthyretin: Insights from the Brazilian multicenter REACT-SP registry

Doctor K. Rafael De Paula Morales (Sao Paulo, BR)

Abstract Slides Video

Presentation thumbnail

Amyloid cardiomyopathy: specificities of transthyretin v30 mutation compared to wild type forms

Doctor M. Pereira Santos (Porto, PT)

Abstract Slides Video

Presentation thumbnail

Misdiagnosis rates in ATTR-CM patients and associated symptoms

Mr P. Collins (London, GB)

Abstract Slides Video

Presentation thumbnail

A systematic review and meta-analysis of diagnostic performance of various echocardiographic parameters in cardiac amyloidosis.

Doctor S. Bouloukou (Thessaloniki, GR)

Abstract Slides Video

Presentation thumbnail

Multiple musculoskeletal procedures and the associated risk of amyloidosis. A Danish nationwide cohort study

Doctor N. Noory (Copenhagen, DK)

Abstract Slides Video

Access the full session

Session thumbnail

Improving diagnosis of cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Hereditary transthyretin amyloidosis caused by Val142Ile variant in Spain: phenotypic characteristics, geographic distribution and population frequency.

Congress Presentation

Approach to family screening in hereditary transthyretin cardiac amyloidosis

Congress Presentation

Transthyretin amyloid cardiomyopathy (ATTR-CM) cardiogenomics: a tertiary centre experience

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources